Sign up
Pharma Capital

The Hydroponics Company welcomes Canadian bill to legalise recreational cannabis

Canada will be the largest developed nation to legalise nationwide recreational use.
cannabis leaf
Bill passed by Canada’s senate

The Hydroponics Company Limited (ASX:THC) stands to gain from the C-45 Bill that has been passed by Canada’s senate on June 7 to legalise adult recreational use of cannabis in Canada.

The Cannabis Act is a milestone toward the end of prohibition of recreational cannabis in Canada and is expected to be an  important driver of growth for THC’s hydroponics division.

Canada will be the largest developed nation to legalise nationwide recreational use for adults over the age of 18.

While medicinal cannabis has been legal in Canada since 2001, the recreational market has remained very fragmented without an established legal framework.

Significant opportunity to grow revenue streams in Canada

THC chairman Steven Xu said: “A decision to legalise recreational use of cannabis will open up a significant opportunity for THC to augment our established revenue streams in Canada, where we supply +600 products, have nine trademarks for hydroponic equipment and growing mediums and plan to execute potential value- accretive acquisitions that will deliver substantial revenue growth for the company in the near term.”

READ: The Hydroponics Company acquires world-class biomanufacturing facility, shares up

The company recently acquired biomanufacturing facilities in Queensland, pushing THC to the forefront of the Australian medicinal cannabis industry.

The facility is one of the largest pharmaceutical botanicals extraction and refinement plants in the Southern Hemisphere.

Register here to be notified of future THC Company articles
View full THC profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.